Astrocyte Pharmaceuticals Announces Journal Publication Stroke of Results Supporting Advancement of AST-004 in Clinic


GROTON, Connecticut – (COMMERCIAL THREAD) – Astrocyte Pharmaceuticals Inc., a drug discovery and development company offering novel neuroprotective therapies for the treatment of brain damage, today announced the publication of a manuscript in the peer-reviewed journal Stroke titled: Adenosine A1R / A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 reduces cerebral infarction in a non-human primate model of stroke. The manuscript describes the results of preclinical studies using AST-004, Astrocyte’s primary drug candidate, for the treatment of stroke.

“According to the Centers for Disease Control (CDC) every 40 seconds a person in the United States has a stroke and every four minutes a person dies from a stroke,” said William Korinek, PhD, CEO of Astrocyte Pharmaceuticals. “This key study in non-human primates was designed to replicate what typically happens when human stroke patients are treated in the emergency room. The results published today in Stroke show very significant improvements across a number of parameters, with benefits beyond the current standard of care – reperfusion by thrombectomy. Based on this data and the broad safety profile, we plan to launch a phase 1 clinical trial in the first half of 2022. ”

The manuscript published in Stroke used a sophisticated model of stroke in a non-human primate with the study conducted by researchers at Astrocyte Pharmaceuticals and Hamamatsu Pharma Research, Inc. of Japan. Administration of AST-004 resulted in rapid and statistically significant decreases in lesion growth rate and total lesion volume. Treatment with AST-004 was well tolerated and no adverse side effects were observed. Researchers from the Department of Cell Systems and Anatomy at the University of Texas at San Antonio Health Sciences Center and the Department of Neuroscience at the University of Warwick, UK, collaborated on the research .

“Our new approach focuses on increasing energy metabolism in astrocytes, which are the brain’s natural guardian cells and play an essential restorative role during stress or brain injury,” said Theodore E. Liston, PhD, vice -research chair, Astrocyte Pharmaceuticals and senior author. “The results published today in Stroke suggest that AST-004, our small agonist molecule that targets astrocyte receptors, could significantly protect brain tissue during and after ischemia in stroke. Administration of AST-004 altered the trajectory of stroke, with lesion growth rates slowing more than twice and reducing ultimate brain damage by up to 45% beyond the benefits of reperfusion surgery single. Treatment with AST-004 also preserved more of the brain tissue from penumbra during ischemia, which could potentially allow more stroke patients to reach hospitals and receive additional procedures such as stroke. surgical intervention.

“AST-004 is a particularly interesting approach because it could potentially be used in a very wide range of stroke patients,” said Jeffrey L. Saver, MD, director of the University’s Stroke Unit. from California to Los Angeles and Chairman of the Astrocyte Clinical Board. Plank. “The mechanistic and safety profile of AST-004 could allow this treatment to be used pre-hospital, closer to the onset of a patient’s stroke, alongside a thrombolytic drug, and to be used in stroke patients who may or may not be candidates for reperfusion surgery. If successful in future human clinical trials, AST-004 could dramatically change the way strokes are treated, improving the outlook for the roughly 13 million Americans who suffer stroke each. year.

About Astrocyte Pharmaceuticals Inc.

Astrocyte Pharmaceuticals Inc. is a privately held drug discovery and development company dedicated to accelerating the recovery and well-being of patients with brain injury. The company is committed to proving the neuroprotective benefits of enhancing astrocyte function and advancing breakthrough therapeutic agents for the treatment of brain damage resulting from stroke, head trauma, concussion and neurodegenerative disorders such as Alzheimer’s disease. For more information, please visit us at Astrocyte Pharmaceuticals Inc.


Comments are closed.